

The Eye-D Insert

Sustained Release for
Glaucoma Management

A BioLight Company



Glaucoma Management Challenge

- 1st cause of irreversible blindness worldwide
- Chronic, lifelong treatment
- Disease progression is irreversible

- A plethora of reasonably effective topical treatments available

- Treatment compliance as low as 25%
- Impacts quality of life

Eye-D Technology

A sub-conjunctival biocompatible insert


Latanoprost – the #1 generic API (>70%)

3 months of treatment (potentially 12)

505(b)(2) pathway (drug product)

Granted US & EU patents

Successfully completed a phase I/IIa under FDA




Latanoprost free acid arginine




Inserter's Design & Use

Off-the-shelf IOL injector ;
Repurposed




Procedure Outline



Release Rate

In-Vitro

High Dose Insert - 12 Months Elution Curves




Phase I/IIa Outcomes

Under FDA ; US sites only

Safety demonstrated

Efficacy demonstrated

Eye-D High Dose Vs. Topical Latanoprost



Development Route

Validate new dose & form of product:
15 patients per arm, 2 dosages, 3+3 months

<\$2M

Phase 2b (potentially phase II/III):
2X dose, double-dummy design, 60 pts per arm
(180 in total), 3 months* study.

<\$15M

Phase 3:
Single dose, double-dummy design, 60± pts per arm
(120 in total), 3 months* study.

The Glaucoma Market

80M patients worldwide*





Globally under-diagnosed
and under-treated

Risk factors: age,
diabetes, smoking and more

\$6.6BN - global market in 2019
6.1% CAGR towards 2027*



Competitive Landscape

	Eye-D	Evolute	Bimatoprost SR	iDose
Product description	<ul style="list-style-type: none"> • A subconjunctival implant • Over 3 months treatment 	<ul style="list-style-type: none"> • A punctal plug drug delivery system • It lasts for up to 3 months 	<ul style="list-style-type: none"> • An intracameral bio-degradable implant • A very limited claim allowing a single 3 months treatment use 	<ul style="list-style-type: none"> • An intracameral non-degradable implant • Effectiveness for up to 12 months
Ownership				
API	Latanoprost (proprietary)	Latanoprost	Bimatoprost	Travoprost
Insert's placement	Sub-conj	Lacrimal canal	Intraocular	Intraocular
OR required	No	No	No	Yes
Development stage	Phase-II	Phase-II	Launched	Phase-III
Comments		Years of development with limited success	Potential risk involved deters regulators	Limited to a single cataract procedure use


Pricing Point

Type	Product (manufacturer)	Dose per eye			MD's comp
		3m	6m	3m cost (6m)	
Sub-conjunctival	Eye-D® (Vi-Sci)	1 insert		\$800	\$400
Drops	Xalatan® (Pfizer)	90 drops	180 drops	> \$600 (> \$1800) generic @ 10% cost	--
Drops	Rocklatan® (Aerie)	90 drops	180 drops	> \$900 (> \$2,700)	--
Intracameral	Durysta® (Allergan)	1 insert	-- off label only	> \$2,000	\$200
Trabecular stent	iStent® (Glaukos)	1 insert Cataract surgery		> \$1,000	>\$2,500

Case Study - A \$95M Cash + Milestones Deal



Following a successful phase-II* Allergan purchases **Helios insert**, an ocular ring for the management of glaucoma by Foresight-Vision 5



● Helios insert + artificial tears (n=63) ▲ Timolol solution + artificial tears (n=64)

No clinical development published since 2018

Competitive Landscape		Eye-D	Evolute	Bimatoprost SR	iDose
Product description		• A subconjunctival implant • Over 3 months treatment	• A punctal plug drug delivery system It lasts for up to 3 months	• An intracameral biodegradable implant • A very limited claim allowing a single 3 months treatment use	• An intracameral non-degradable implant • Effectiveness for up to 12 months
Ownership		BIOLIG	mati	Allergan	GLAUKOS
API		Latanoprost (proprietary)	Latanoprost	Bimatoprost	Travoprost
Insert's placement		Sub-conj	Lacrimal canal	Intraocular	Intraocular
OR required		No	No	No	Yes
Development stage		Phase-II	Phase-II	Launched	Phase-III
Comments		Helios insert	Years of development with limited success	Potential risk involved deltar regulators	Limited to a single cataract procedure use



* J.D. Brandt, Ophthalmology 123(8), 1685, 2016

Product Development Status

API
GMP batch ready

Technology
Worldwide
License

Production
Modified scalable
method applied

All US suppliers

Inserter
Development
completed

Confirmation Study
preps underway

Intellectual Property

Insert family –
Granted US & EU

Latanoprost-Arginine salt family –
Granted US & EU

Inserter' bayonet PCT -
Submitted

Potential Pipeline

Topical application for latanoprost salt

Veterinary application for canines
(granted MUMS status)

Seeking additional API to
leverage the platform

Summary

Financing Sought -
\$3M

Financing goal -
Completing confirmation study
and analytical work

Next milestone -
Collaboration / acquisition

Thank You!

Yoni Manor, CEO

ymanor@vi-sci.com

+972-54-6689445

